Laboratory-developed tests for an array of patient outcomes – from response to cancer treatments to predisposition to cardiovascular disease – should be regulated closely by the Food and Drug Administration, according to Congressional testimony on Tuesday.

“As our knowledge of the genetic underpinnings of cardiovascular disease expands, we anticipate there […]